特立帕肽联合唑来膦酸治疗成骨不全症随机临床试验
该多中心开放标签平行组随机试验纳入350例成骨不全症成人患者,比较特立帕肽联合唑来膦酸与标准治疗的骨折风险。结果显示联合治疗未降低影像证实的骨折风险,但显著提高腰椎和全髋骨密度,提示骨折发生更取决于骨质量而非骨密度。
要点
- 特立帕肽联合唑来膦酸未降低成骨不全症成人骨折风险
- 联合治疗显著提高腰椎与全髋骨密度
- 骨折发生更取决于骨质量而非低骨密度
核心结论
- 在成骨不全症成人中,特立帕肽联合唑来膦酸较标准治疗未降低骨折风险,尽管骨密度显著升高,提示骨质量下降而非骨密度低是骨折发生的关键。
研究设计与样本
- 多中心、开放标签、平行组随机临床试验,2017年5月17日至2025年3月21日在27家转诊中心开展。
- 350例临床诊断成骨不全症成人随机分组,176例接受特立帕肽联合唑来膦酸,174例接受标准治疗,1例退出,349例可评估。
- 平均年龄43.7岁,女性188例(53.9%);骨密度用双能X线吸收法测定,骨折经影像确认并由盲法评审裁定。
主要发现
- 联合治疗组176例中65例(36.9%)发生新发骨折,标准治疗组173例中63例(36.4%)发生,绝对风险降低-1.57%(95%CI -9.90%至5.89%),风险比0.97(95%CI 0.68至1.38)。
- 联合治疗组腰椎和全髋骨密度增加显著多于标准治疗组。
- 多项生活质量指标偏向联合治疗组,两组不良事件相似。
关键数值与推荐
- 活动组:特立帕肽20 μg每日皮下注射2年,随后输注唑来膦酸5 mg。
- 标准治疗组可使用双膦酸盐及其他骨靶向药物,但禁用特立帕肽和其他骨合成代谢药物。
- 主要终点为盲法裁定、影像证实的 incident 骨折参与者人数。
临床怎么用
- 对成骨不全症成人,不应仅以提升骨密度为目标而期望降低骨折风险,需综合评估骨质量与个体化治疗。
- 特立帕肽联合唑来膦酸可考虑用于改善骨密度及部分生活质量指标,但需权衡其未降低骨折风险的证据。
局限性
- 开放标签设计可能影响部分主观终点评估。
- 随访期内骨折事件数有限,置信区间较宽,不能排除较小效应。
- 研究人群以I型成骨不全症为主,结论外推至其他类型需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Osteogenesis imperfecta causes multiple fractures throughout life, causing substantial morbidity. OBJECTIVE: To determine whether the parathyroid hormone analogue teriparatide followed by zoledronic acid reduces the risk of fractures in adults with osteogenesis imperfecta. DESIGN, SETTING, AND PARTICIPANTS: Multicenter open-label, parallel-group, randomized clinical trial, conducted between May 17, 2017, and March 21, 2025, in adults attending one of 27 referral centers with a clinical diagnosis of osteogenesis imperfecta. Bone mineral density (BMD) was measured by dual x-ray absorptiometry and bone turnover by serum procollagen type 1 N-terminal propeptide and C-terminal telopeptide of type 1 collagen. Fractures were confirmed by skeletal imaging. Several measures of health-related quality of life were assessed. INTERVENTIONS: Those in the active group received 20 μg of teriparatide daily by subcutaneous injection for 2 years followed by an infusion of 5 mg of zoledronic acid. In the standard care group, bisphosphonates and other bone-targeted medicines could be used but teriparatide and other bone anabolic drugs were prohibited. MAIN OUTCOMES AND MEASURES: The primary end point was the number of participants with imaging-proven incident fractures adjudicated by reviewers blinded to treatment allocation. Secondary end points included the total number of fractures, changes in BMD, biochemical markers of bone turnover, and health-related quality of life. RESULTS: Of the 350 individuals randomized, 176 were allocated to receive teriparatide plus zoledronic acid, 174 to standard care, and 1 withdrew, leaving 349 evaluable participants. The mean age was 43.7 years (188 females [53.9%]). Most had type I osteogenesis imperfecta caused by pathogenic variants in the type 1 collagen genes. In the teriparatide plus zoledronic acid group 65 of 176 (36.9%) had incident fractures compared with 63 of 173 (36.4%) in the standard care group (absolute risk reduction, -1.57%; 95% CI, -9.90% to 5.89%; hazard ratio, 0.97; 95% CI, 0.68 to 1.38). Lumbar spine and total hip BMD increased significantly more with teriparatide plus zoledronic acid than standard care. Several quality-of-life measures favored teriparatide plus zoledronic acid. Adverse events were similar in both groups. CONCLUSIONS AND RELEVANCE: This randomized clinical trial among adults with osteogenesis imperfecta found that teriparatide plus zoledronic acid did not reduce fracture risk compared with standard care despite significantly increasing BMD, suggesting the importance of reduced bone quality rather than low bone density in the pathogenesis of fracture. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN15313991.
引用
- Hald JD, Weir CJ, Keerie C, et al. Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. JAMA. 2026. PMID: 42133304. doi:10.1001/jama.2026.6889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。